Lupin receives tentative USFDA nod for generic Azilsartan Medoxomil tablets

Homegrown pharmaceuticals major Lupin on Friday said it has received tentative approval from the US health regulator for its generic Azilsartan Medoxomil tablets used to treat high blood pressure.

The tentative approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) Azilsartan Medoxomil tablets is for strengths of 40 mg and 80 mg, Lupin said in a regulatory filing.

These are generic equivalent of Edarbi tablets, 40 mg and 80 mg of Arbor Pharmaceuticals, LW, it added.

“This product will be manufactured at Lupin’s Nagpur facility in India,” the company said. Citing IQVIA moving annual total (MAT) September 2021 data, the company said the Azilsartan Medoxomil tablets had estimated annual sales of USD 103.4 million in the US.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor